Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Express Scripts
Dow
Johnson and Johnson
Mallinckrodt

Last Updated: August 19, 2022

Investigational Drug Information for SGI-110


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for SGI-110?

SGI-110 is an investigational drug.

There have been 30 clinical trials for SGI-110. The most recent clinical trial was a Phase 3 trial, which was initiated on March 19th 2015.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Astex Pharmaceuticals, Inc., Astex Pharmaceuticals, and National Cancer Institute (NCI).

There are nine US patents protecting this investigational drug and one hundred and forty-five international patents.

Recent Clinical Trials for SGI-110
TitleSponsorPhase
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaNational Cancer Institute (NCI)Phase 2
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Astex Pharmaceuticals, Inc.Phase 2
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Bristol-Myers SquibbPhase 2

See all SGI-110 clinical trials

Clinical Trial Summary for SGI-110

Top disease conditions for SGI-110
Top clinical trial sponsors for SGI-110

See all SGI-110 clinical trials

US Patents for SGI-110

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SGI-110 See Plans and Pricing Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) See Plans and Pricing
SGI-110 See Plans and Pricing Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) See Plans and Pricing
SGI-110 See Plans and Pricing Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Express Scripts
Dow
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.